Hydrocodone extended-release - Teva Pharmaceutical Industries

Drug Profile

Hydrocodone extended-release - Teva Pharmaceutical Industries

Alternative Names: CEP-33237; Hydrocodone bitartrate extended-release - Teva; Tamper-deterrent hydrocodone; Twice-daily hydrocodone - Teva; VANTRELAER

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Teva Pharmaceutical Industries
  • Class Antitussives; Morphinans; Opioid analgesics; Opioid peptides; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Pain

Most Recent Events

  • 12 Dec 2017 Hydrocodone extended-release tablets is still at registered stage for Pain in USA (PO) (Teva pharma website, December 2017)
  • 18 Jan 2017 Registered for Pain in USA (PO) - First global approval
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain in Canada (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top